Intrinsic Value of S&P & Nasdaq Contact Us

Equillium, Inc. EQ NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.00
-51.2%

Equillium, Inc. (EQ) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 9 Buy, 2 Hold.

The consensus price target is $1.00, representing a downside of 51.2% from the current price $2.05.

Analysts estimate Earnings Per Share (EPS) of $-0.38 and revenue of $0.04B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.23 vs est $-0.38 (beat +38.7%). 2025: actual $-0.39 vs est $-0.41 (beat +5.5%). Analyst accuracy: 66%.

EQ Stock — 12-Month Price Forecast

$1.00
▼ -51.22% Downside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Equillium, Inc., the price target is $1.00.
The average price target represents a -51.22% change from the last price of $2.05.

EQ Analyst Ratings

Buy
11
Ratings
9 Buy
2 Hold
Based on 11 analysts giving stock ratings to Equillium, Inc. in the past 3 months
Rating breakdown
Buy
9 82%
Hold
2 18%
82%
Buy
9 analysts
18%
Hold
2 analysts
0%
Sell
0 analysts

EPS Estimates — EQ

66%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024 Actual –$0.23 vs Est –$0.38 ▲ 63.0% off
2025 Actual –$0.39 vs Est –$0.41 ▲ 5.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — EQ

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual $0.041B vs Est $0.037B ▲ 10.3% off
2025 Actual $0.000B vs Est $0.011B ▼ 8,361.5% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message